The Alliance for Clinical Trials in Oncology will host a public webinar on Monday, September 29, at 12 pm CT showcasing the key findings of Alliance research presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. The clinical trial results discussed at the virtual meeting will include some of the latest information for people living with colorectal, squamous cell, and renal cell cancers.
“We are pleased to showcase the ground-breaking research that Alliance researchers presented at ASCO,” said Evanthia Galanis, MD, Group Chair of the Alliance, Sandra J. Schulze Professor of Novel Therapeutics and Professor of Oncology at the Mayo Clinic in Rochester, Minn. “Our panel of investigators will explain how the latest results of their research can impact the current standard of care for patients with cancer.”
“Many clinical trials conducted by the Alliance have meaningfully impacted the care of cancer patients and resulted in new standards of treatment,” said Olwen Hahn, MD, Director and Principal Investigator of the Alliance Central Protocol Operations Program and an Associate Professor of Medicine at the University of Chicago Medical Center. “During this 90-minute webinar, our expert researchers will review the latest results of their studies to help clinicians and patients with cancer best interpret the results.”
Panelists include:
- Dan Zanberg, MD, UPMC Cancer Center: Dr. Zanberg will present the results of Alliance A091802: A phase II randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma.
- Sara Char, MD, Dana Farber Cancer Institute: Dr. Char will discuss the results of CALGB/SWOG (Alliance) 80702: Association between empirical dietary inflammatory pattern and survival in patients with stage III colon cancer.
- Frank Sinicrope, MD, Mayo Clinic: Dr. Sinicrope will present the findings of Alliance A021502-ATOMIC: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair.
- Ellen Smith, PhD, University of Alabama School of Nursing: Dr. Smith will review the findings of Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled phase II study.
- Tian Zhang, MD, University of Texas Southwestern Medical Center: Dr. Zhang will discuss Alliance A031704: Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma treated on the phase III PDIGREE (A031704) trial: results from Step 1 analysis.
The event is free and open to the public. Register today.
# # #
The Alliance for Clinical Trials in Oncology is a national leader in advancing cancer research, uniting more than 25,000 cancer specialists at 115 main institutions and 1,400 affiliates across the U.S. and Canada. As part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program, the Alliance conducts pioneering, practice-changing clinical trials that improve outcomes and reshape standards of care. Our work has led to multiple FDA approvals, influenced national guidelines, and produced hundreds of high-impact publications. More than 40,000 participants have taken part in Alliance studies, and our growing biospecimen repository now includes more than 1.5 million samples, collected over the past 30 years. Learn more at www.AllianceforClinicalTrialsinOncology.org.